BioNTech firm, based by scientists Özlem Türeci and Uğur Şahin, who proceed their work in Germany, resulting from their vaccine growth in opposition to the coronavirus epidemic. “Individuals of the 12 months” was chosen.
Türeci and Şahin, in an announcement to the German press, said that their new target is to develop a cancer vaccine.
INDIVIDUAL VACCINE AGAINST CANCER
There are remedy strategies reminiscent of chemotherapy, radiation remedy and stem cell transplantation within the combat in opposition to cancer. The Turkish couple continues to work so as to add the vaccine to those.
Türeci and Şahin, who gave an interview to Bild, stated that they needed to develop a person vaccine in opposition to cancer.
Uğur Şahin said that they’re presently within the Part-2 section, “We’re taking a look at whether or not our vaccines can present enchancment for sufferers in comparison with the usual of care.” he stated.
It was famous that groundbreaking knowledge units might be revealed within the subsequent two years, and the primary software might be realized in 2023.
“WE WANT TO USE IT FOR CANCER TREATMENT”
Ozlem Tureci, “Once we realized the necessity for enchancment in cancer drugs a few years in the past, we thought: The immune system is key and we wish to develop immune remedy.
Which means that we wish to use the mechanisms that the immune system has developed over hundreds of thousands of years of evolution, particularly for the remedy of cancer, within the combat in opposition to viruses or micro organism.” used the phrases.
IT WILL BE READY IN A FEW YEARS
Stating that they’re doing analysis for the usage of vaccine expertise in opposition to cancer cells and tumors, Türeci stated in a earlier assertion, “Now we have totally different cancer vaccines based mostly on mRNA. In a couple of years we will probably be prepared to supply our vaccine to combat cancer to individuals.” he stated.
#Uğur #Şahin #Özlem #Türecis #target #cancer #vaccine